Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion

Cannella, Laura; Latagliata, Roberto; Breccia, Massimo; Carmosino, Ida; Loglisci, Giuseppina; Volpicelli, Paola; Ferretti, Antonietta; Santopietro, Michelina; Vozella, Federico; Girmenia, Corrado; Cuzzola, Mariella; Olíva, Esther Natalie

doi:10.1007/s00277-011-1263-7

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, it is still unclear how long lenalidomide treatment should be maintained in the responding patients. It is well documented that some patients who discontinued lenalidomide very early because of unacceptable toxicity achieved a complete disease remission after the treatment discontinuation; however, many of those patients relapsed after a variable period . In addition, no data are available about treatment discontinuation in responder patients enrolled in the most important and larger clinical trials, and it is common (but uncontrolled) opinion that lenalidomide should be continued up to disease relapse.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

Vozella

Latagliata

Carmosino

et al. 2014

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

Lenalidomide induces in patients with myelodysplastic syndrome (MDS) and del(5q) erythroid and cytogenetic response rates as high as 75% and 50%, respectively. It is still unclear, however, how long lenalidomide treatment should be continued and whether or not the drug could be interrupted. To assess the feasibility of lenalidomide discontinuation, we revised a cohort of 16 low-risk MDS patients with del(5q) treated at our institute in a phase II multicentric Italian study. Among the 12 responding patients, four discontinued lenalidomide while in complete response. All four patients needed during treatment a permanent lenalidomide reduction from 10 to 5 mg/day because of haematological toxicity (three patients) or grade 3 muscular and bone pain (one patient). At lenalidomide discontinuation after 16, 20, 27 and 20 months from the start, respectively, all four patients were in complete hematologic response and three forth in complete cytogenetic response. Three patients are still in response after 36, 30 and 20 months from lenalidomide discontinuation, respectively: The remaining patient relapsed after 20 months, and she is now receiving a new course of lenalidomide. In conclusion, long-lasting remissions are achievable in MDS patients with del(5q) in complete response after lenalidomide discontinuation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…There are recent reports on patients who discontinued lenalidomide after a variable period of treatment, mainly because of toxicity who experienced a long‐lasting remission . It is still unclear, however, how long lenalidomide treatment should be continued and whether or not the drug should be interrupted in responding patients.…”

Section: Introductionmentioning

confidence: 99%

Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

Vozella

Latagliata

Carmosino

et al. 2014

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, in recent years, the use of lenalidomide in the management of anemia related to 5q- syndrome has significantly changed the clinical scenario in this specific setting [1]. Several reports have described durable erythroid responses and the achievement of transfusion independence in patients with 5q- syndrome who were treated with lenalidomide despite the discontinuation of this agent and the persistence of the underlying malignant clone [1, 2, 3, 4]. In addition, both anemia and transfusion are paradoxically associated with organ injury [5], for which iron chelation therapy (ICT) plays an expanding role in the global management of transfusion-dependent patients with MDS.…”

mentioning

confidence: 99%

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy

et al. 2014

View full text Add to dashboard Cite

Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases

Himmelmann¹,

Tchinda

2012

Leukemia Research

View full text Add to dashboard Cite

Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion

Cited by 3 publications

References 7 publications

Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy

Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases

Contact Info

Product

Resources

About